METABOLIC SYNDROME ASSOCIATED COMPLICATIONS

Authors

  • Damini Nerkar Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi 835215 Jharkhand, India
  • Aniruddha Mukherjee Gupta College of Technological Sciences
  • Bina Kumari Mehta Birla Institute of Technology
  • Sugato Banerjee Birla Institute of Technology

Keywords:

Arthritis, Cancer, Cognitive impairment, Depressive disorders, Metabolic syndrome, Neuropathy

Abstract

Metabolic syndrome (MetS) is characterized by a cluster of disorders like obesity, insulin resistance, glucose intolerance, hypertension and dyslipidemia. All these disorders are responsible for the development of secondary morbid and co-morbid conditions. The current review focuses on the molecular pathogenesis of secondary late complications associated with metabolic syndrome including cognitive impairment, depressive disorder, neuropathy, arthritis and colorectal cancer.

 

Downloads

Download data is not yet available.

References

Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabetic Med 2006;23(5):469-80.

www.idf.org/metabolic-syndrome

Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States. National Health Statistics Report 2005;5(13):1-7.

Riccardi G, Giacco R, Rivellese AA. Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr 2004;23(4):447-56.

Enas EA, Chacko V, Pazhoor SG, Chennikkara H, Devarapalli HP. Dyslipidemia in south asian patients. Curr Atheroscler Rep 2007;9(5):367-74.

Reaven G. Metabolic syndrome: Pathophysiology and implications for management of cardiovascular disease. Circulation 2002;106(3):286-8.

Taylor VH, MacQueen GM. Cognitive dysfunction associated with metabolic syndrome. Obes Rev 2007;8:409-18.

Gatto NM, Henderson VW, St John JA, McCleary C, Hodis HN, Mack WJ. Metabolic syndrome and cognitive function in healthy middle-aged and older adults without diabetes. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 2008;15(5):627-41.

McCall AL. Altered glycemia and brain-update and potential relevance to the aging brain. Neurobiol Aging 2005;26:70–5.

Hayden MR, Banks WA, Shah GN, Gu Z, Sowers JR. Cardiorenal metabolic syndrome and diabetic cognopathy. CardioRenal Med 2013;3:265-82.

Wang M. The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr Metab (Lond) 2005;2:3.

Pereira CD, Azevedo I, Monteiro R, Martins MJ. Hydroxysteroid dehydrogenase type I: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus. Diabetes Obes metab 2012;14:868-81.

Vicennati V, Pasqui F, Cavazza C, Pagotto U, Pasquali R. Stress–related development of obesity and cortisol in women. Obesity 2009;17(9):1678-83.

McCarty MF. Enhancing central and peripheral insulin activity as a strategy for the treatment of endogenous depression-an adjuvant role for chromium picolinate. Med Hypotheses 1994;43(4):247-52.

Convit A. Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiol Aging 2005;26:31–5.

Horners HC, Packan DR, Sapolsky RM. Glucocorticoids inhibit glucose transport in cultured hippocampal neurons and glia. Neuroendocrinology 1990;52:57–64.

Misiak B, Leszek J, Kiejna A. Metabolic Syndrome, mild cognitive Impairment and Alzheimer’s disease-the emerging role of systemic low grade inflammation and adiposity. Brain Res Bull 2012;89(3-4):144-9.

De Groot JC, De Leeuw FE, Oudkerk M, Gijn JV, Holfman A, Jolles J, et al. Cerebral White matter lesions and cognitive function. Ann Neurol 2000;47(2):145-51.

Purkayastha S, Fadar O, Mehregan A, Salat DH, Moscufo N, Meier Ds, et al. Impaired cerebrovascular hemodynamics is associated with cerebral white matter damage. J Cereb Blood Flow Metab 2014;34(2):228-34.

Bokura H, Yamaguchi S, Lijima K, Nagai A, Oqura H. Metabolic syndrome is associated with silent ischemic brain lesions. Stroke 2008;39:1607-9.

Smith AG. Impaired glucose tolerance and metabolic syndrome in idiopathic neuropathy. J Peripher Nerv Syst 2012;17(Suppl 2):15-21.

Hinder LM, Vivekanandan-Giri A, McLean LL, Pennathur S, Feldman EL. Decreased glycolytic and tricarboxylic acid cycle intermediates coincide with peripheral nervous system oxidative stress in a murine model of type 2 diabetes. J Endocrinol 2013;216:1–11.

Vincent AM, Callaghan BC, Smith AL, Feldman E. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol 2011;7:573–83.

Lupachyk S, Watcho P, Obrosov AA, Stavniichuk R, Obrosova IG. Endoplasmic reticulum stress contributes to prediabetic peripheral neuropathy. Exp Neurol 2013;247:342–8.

Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 2013;339:172–7.

Collaghan B, Feldman E. The Metabolic syndrome and neuropathy: Therapeutic challenges and opportunities. Ann Neurol 2013;74:397-403.

Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010;72:219–46.

Patel S, Santani D. Role of NF-KB in the pathogenesis of Diabetes and its associated complications. Public Relations 2009;61:595-603.

Dunbar JA, Reddy P, Davis-Lameloise N, Philpot B, Laatikainen T, Kilkkinen A, et al. Depression: an important comorbidity with metabolic syndrome in a general population. Diabetes Care 2008;31(12):2368-73.

Vanhala M, Jokelainen J, Keinänen-Kiukaanniemi S, Kumpusalo E, Koponen H. Depressive symptoms predispose females to metabolic syndrome: A 7-year follow-up study. Acta Psychiatr Scand 2009;119(2):137-42.

Southwick SM, Vythilingam M, Charney DS. The psychobiology of depressionand resilence to stress: implications to prevention and treatment. Annu Rev Clin Psychol 2005;1:255-91.

Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010;140(6):918-34.

Nishimura S, Manabe I, Nagai R. Adipose tissue inflammation in obesity and metabolic syndrome. Discovery Med 2009;8(41):55-60.

Vernochet C, Damilano F, Mourier A, Bezy O, Mori MA, Smyth G, et al. Adipose tissue mitochondrial dysfunction triggers a lipodystrophic syndrome with insulin resistance, hepatosteatosis, and cardiovascular complications. FASEB J 2014;28(10):4408-19.

Musatov S, Chen W, Pfaff DW, Charles V, Yang XJ, Clegg DJ, et al. Silencing of estrogen receptor alpha in the ventromedial nucleus of hypothalamus leads to metabolic syndrome. Proc Natil Acad Sci 2007;104(7):2501-6.

Kim Y-K, Na K-S, Shin K-H. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1044-53.

Eller T, Vasar V, Shlik J, Maron E. Proinflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:445-50.

Kiecolt-Glaser JK, Glaser R. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res 2002;53:873–6.

Studd JW. A guide to the treatment of depression in women by estrogens. Climacteric 2011;14(6):637-42.

Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev 2013;34(3):309-38.

Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol 2014;41(7):1357-65.

Maiti R, Agrawal NK. Atherosclerosis in diabetes mellitus: Role of inflammation. Indian J Med Sci 2007;61(5):292-306.

Love TJ, Zhu Y, Zhang Y, Wall-Burns L, Ogdie A, Gelfand JM, Choi HK. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 2012;71(8):1273-7.

Cecilia P, Chung AO, Joseph FS, Ingrid A, Tebeb G, Ayumi S, et al. Prevalence of metabolic Syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008;196(2):756-63.

Sidiropoulos PI, Karvounaris SA, Boumpas DT. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology and clinical implications. Arthritis Res Ther 2008;10(3):207.

Hurlimann D, Enseleit F, Ruschitzka F. Rheumatoid arthritis, inflammation, and atherosclerosis. Herz 2004;29(8):760-8.

Kim JH, Lim YJ, Kim Y, Sung I, Shim SG, Oh S, et al. Is metabolic syndrome a risk factor for colorectal adenoma? Cancer Epidemiol Biomarkers Prev 2007;16(8):1543-6.

Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer a systematic review and meta-analysis. Diabetes Care 2012;35(11):2402-11.

Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999;91(13):1147-54.

Bruce WR, Wolever TMS, Giacca A. Mechanisms linking diet and colorectal cancer: The possible role of insulin resistance. Nutr Cancer 2000;37(1):19-26.

Hubbard SR. Structural biology: Insulin meets its receptor. Nature 2013;493(7431):171-2.

Tennagels N, Werner U. The metabolic and mitogenic properties of basal insulin analogues. Arch Physiol Biochem 2013;119(1):1-14.

Wajchenberg BL, Cohen RV. Adipose tissue and type 2 diabetes mellitus. In: Fantuzzi G, Braunschweig C. editor. Adipose Tissue and Adipokines in Health and Disease. New York: Humuna press; 2014. p. 53-76.

Otake S, Takeda H, Suzuki Y, Fukui T, Watanabe S, Ishihama K, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: Evidence for participation of insulin resistance. Clin Cancer Res 2005;11(10):3642-6.

Young NJ, Metcalfe C, Gunnell D, Rowlands M, Lane JA, Gilbert R, et al. A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom. Cancer Causes Control 2012;23(6):907-17.

Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 2010;21(10):610-8.

Brakenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004;101(8):2476-81.

Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4(8):579-91.

Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules adipocyte-derived plasma protein adiponectin. Circulation 1999;100(25):2473-6.

Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer 2006;94(9):1221-5.

Powell D, Suwanichkul A, Cubbage ML, DePaolis LA, Snuggs MB, Lee PDK. Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J Biol Chem 1991;266(28):18868-76.

Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002;94(13):972-80.

Chiefari E, Tanyolaç S, Iiritano S, Sciacqua A, Capula C, Arcidiacono B, et al. A polymorphism of HMGA1 is associated with increased risk of metabolic syndrome and related components. Sci Rep 2013;3:1-6.

Chiefari E, Tanyolac S, Paonessa F, Pullinger CR, Capula C, Iiritano S, et al. Functional variants of the HMGA1 gene and type 2 diabetes mellitus. JAMA 2011;305(9):903-12.

Brunetti A, Chiefari E, Foti D. Recent advances in the molecular genetics of type 2 diabetes mellitus. World J Diabetes 2014;5(2):128-40.

Published

01-07-2015

How to Cite

Nerkar, D., A. Mukherjee, B. K. Mehta, and S. Banerjee. “METABOLIC SYNDROME ASSOCIATED COMPLICATIONS”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 7, July 2015, pp. 22-25, https://www.innovareacademics.in/journals/index.php/ijpps/article/view/6169.

Issue

Section

Review Article(s)